Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Explorative Trial to Identify the Impact of Denosumab on the Systemic Immunity and Local Immunologic Microenvironment in Postmenopausal Patients With HER2 Negative Breast Cancer

Next Previous
Search
Trial Profile

Explorative Trial to Identify the Impact of Denosumab on the Systemic Immunity and Local Immunologic Microenvironment in Postmenopausal Patients With HER2 Negative Breast Cancer

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary)
  • Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
  • Focus Pharmacodynamics
  • Acronyms PERIDENO

    • Most Recent Events

    • 16 Jan 2020 Planned End Date changed from 1 May 2023 to 1 Jun 2023.
    • 16 Jan 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Feb 2021.
    • 16 Jan 2020 Planned initiation date changed from 1 May 2018 to 1 Feb 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top